Free Trial
NASDAQ:IMTX

Immatics Q1 2025 Earnings Report

Immatics logo
$6.56 +0.11 (+1.71%)
Closing price 04:00 PM Eastern
Extended Trading
$6.56 0.00 (0.00%)
As of 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immatics EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Immatics Revenue Results

Actual Revenue
$20.12 million
Expected Revenue
$14.92 million
Beat/Miss
Beat by +$5.20 million
YoY Revenue Growth
N/A

Immatics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Immatics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Friday, August 8, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Immatics Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Immatics: Taking Off On A PRAME Rocketship
See More Immatics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email.

About Immatics

Immatics (NASDAQ:IMTX), a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

View Immatics Profile

More Earnings Resources from MarketBeat